azalanstat has been researched along with mevalonic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burton, PM; Chiou, M; Dunlap, B; Haller, J; Heller, R; Malonzo, E; Murakami, S; Salari, A; Swinney, DC; Walker, KA | 1 |
| Becker, A; Hrboticky, N; Kruse, HJ; Weber, PC | 1 |
2 other study(ies) available for azalanstat and mevalonic acid
| Article | Year |
|---|---|
Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
Topics: Acetates; Aniline Compounds; Animals; Anticholesteremic Agents; Apolipoproteins B; Cell Line; Cholesterol; Cricetinae; Cytochrome P-450 Enzyme Inhibitors; Dietary Fats; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Mesocricetus; Mevalonic Acid; Microsomes, Liver; Oxidoreductases; Receptors, LDL; RNA, Messenger; Sterol 14-Demethylase; Sulfides | 1995 |
Increased cellular triglyceride levels in human monocytic and rat smooth muscle cells after lovastatin.
Topics: Acetates; Amides; Aniline Compounds; Animals; Anticholesteremic Agents; Cell Line; Cholesterol; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Mevalonic Acid; Monocytes; Muscle, Smooth; Oleic Acid; Organosilicon Compounds; Rats; Rats, Wistar; Sulfides; Triglycerides | 1997 |